You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: RE39155


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: RE39155
Title:Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B
Abstract:Use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of hepatitis B is disclosed. ##STR00001##
Inventor(s): Belleau; Pierrette (Montreal, CA), Nguyen-Ba; Nghe (La Praire, CA), Belleau; Bernard (Westmont, CA)
Assignee: Shire BioChem Inc. (Quebec, CA)
Application Number:09/585,431
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of U.S. Patent RE39155: A Detailed Analysis

Introduction

When analyzing a patent, particularly a reissue patent like U.S. Patent RE39155, it is crucial to delve into the scope and claims to understand its implications and validity. This article will provide a comprehensive analysis of the patent landscape, focusing on the key aspects of patent scope, claim language, and the legal framework governing reissue patents.

What is a Reissue Patent?

A reissue patent is a new patent that is issued to replace an original patent, often to correct errors or to broaden or narrow the claims of the original patent. The process is governed by 35 U.S.C. § 251, which requires that the reissue claims must be directed to the invention disclosed in the original patent[2].

Patent Scope and Claims

Patent scope is a critical aspect of patent analysis, as it defines the boundaries of what is protected by the patent. Two key metrics for measuring patent scope are independent claim length and independent claim count. These metrics can indicate the breadth and clarity of the patent claims[3].

Independent Claim Length

The length of independent claims can be an indicator of the complexity and breadth of the patent. Generally, shorter independent claims are associated with narrower and more focused inventions, while longer claims may indicate broader and more complex inventions.

Independent Claim Count

The number of independent claims also plays a significant role. A higher number of independent claims can suggest a broader scope, but it may also increase the risk of ambiguity and potential litigation.

Legal Framework for Reissue Patents

The legal framework for reissue patents is stringent to ensure that the reissue claims do not exceed the scope of the original patent.

35 U.S.C. § 251

This section requires that the reissue claims must be directed to the invention disclosed in the original patent. The reissue claims cannot introduce new subject matter that was not present in the original patent. This is often referred to as the "original patent" requirement[2].

Case Law Precedents

In cases like In Re FLOAT'N'GRILL LLC, the Court of Appeals for the Federal Circuit has affirmed that reissue claims must strictly adhere to the invention disclosed in the original patent. Any attempt to broaden the claims to cover undisclosed alternatives or features not explicitly described in the original specification is not permissible[2].

Patent Term Adjustment (PTA) and Obviousness-Type Double Patenting (ODP)

Patent Term Adjustment (PTA) and Obviousness-Type Double Patenting (ODP) are important considerations in the context of reissue patents.

Patent Term Adjustment (PTA)

PTA is granted to compensate for delays during the prosecution of a patent. However, as seen in In re Cellect, PTA does not extend the term of a patent beyond the date of a terminal disclaimer. This ensures that the patent term is not unjustly extended, which could lead to divided ownership and potential harassment by multiple assignees[1].

Obviousness-Type Double Patenting (ODP)

ODP prevents an inventor from securing a second, later-expiring patent for an invention covered by a patent that was filed at the same time but has a different patent term due to PTA. This is crucial in maintaining the integrity of the patent system and preventing abuse of the system[1].

Analyzing U.S. Patent RE39155

Claim Language

To analyze the scope of U.S. Patent RE39155, one must carefully review the claim language. Here are some key points:

  • Independent Claims: Examine the length and count of independent claims to determine the breadth and complexity of the invention.
  • Dependent Claims: Understand how dependent claims build upon the independent claims to further define the invention.

Original Patent Requirement

Ensure that the reissue claims comply with the original patent requirement under 35 U.S.C. § 251. This involves verifying that the reissue claims do not introduce new subject matter not disclosed in the original patent.

PTA and ODP Considerations

If the patent has been granted PTA, determine whether the reissue claims respect the terminal disclaimer date and do not violate ODP principles.

Examples and Case Studies

In re Cellect

In this case, the Court of Appeals for the Federal Circuit upheld the Board's decision that the reissue claims were unpatentable under ODP. This highlights the importance of adhering to the statutory language and precedent when dealing with PTA and ODP[1].

In Re FLOAT'N'GRILL LLC

This case illustrates the strict adherence to the original patent requirement. The reissue claims were rejected because they did not cover the invention disclosed in the original patent, demonstrating the critical importance of this requirement[2].

Statistics and Trends

Patent Scope Metrics

Studies using datasets like the USPTO's Patent Claims Research Dataset have shown that narrower claims at publication are associated with a higher probability of grant and a shorter examination process. This underscores the importance of clear and focused claim language[5].

Examination Process

The examination process tends to narrow the scope of patent claims, both in terms of claim length and claim count. This is particularly significant when the duration of examination is longer, indicating that clarity and specificity are key factors in patent prosecution[3].

Key Takeaways

  • Patent Scope: Independent claim length and count are crucial metrics for measuring patent scope.
  • Original Patent Requirement: Reissue claims must strictly adhere to the invention disclosed in the original patent.
  • PTA and ODP: Ensure that PTA does not extend the patent term beyond the terminal disclaimer date and that ODP principles are respected.
  • Claim Language: Clear and focused claim language is essential for successful patent prosecution.
  • Legal Precedents: Adhere to case law precedents to avoid violations of statutory requirements.

FAQs

  1. What is the purpose of a reissue patent?

    • A reissue patent is issued to correct errors or to broaden or narrow the claims of the original patent.
  2. How is patent scope measured?

    • Patent scope can be measured using metrics such as independent claim length and independent claim count.
  3. What is the original patent requirement for reissue patents?

    • The reissue claims must be directed to the invention disclosed in the original patent and cannot introduce new subject matter.
  4. How does Patent Term Adjustment (PTA) affect the patent term?

    • PTA compensates for delays during prosecution but does not extend the patent term beyond the terminal disclaimer date.
  5. What is Obviousness-Type Double Patenting (ODP)?

    • ODP prevents an inventor from securing a second, later-expiring patent for an invention covered by a patent filed at the same time but with a different patent term due to PTA.

Sources

  1. In re Cellect, United States Court of Appeals for the Federal Circuit, August 28, 2023.
  2. In Re FLOAT'N'GRILL LLC, United States Court of Appeals for the Federal Circuit, July 12, 2023.
  3. Patent Claims and Patent Scope, SSRN, September 29, 2016.
  4. US-RE39909-E1 - Tracking system for locational tracking of ..., Unified Patents.
  5. Patent Claims Research Dataset, USPTO, August 28, 2017.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent RE39155

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE39155

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9100039Jan 03, 1991
United Kingdom9109913May 07, 1991
PCT Information
PCT FiledJanuary 03, 1992PCT Application Number:PCT/CA92/00001
PCT Publication Date:July 23, 1992PCT Publication Number: WO92/11852

International Family Members for US Patent RE39155

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 120644 ⤷  Subscribe
Australia 1153492 ⤷  Subscribe
Australia 660650 ⤷  Subscribe
Canada 2100269 ⤷  Subscribe
Canada 2254613 ⤷  Subscribe
Cyprus 2047 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.